Some recent in vitro studies suggested that treatment with sorafenib retained the levels of expression of ABCC1-3, which were significant induced by treatment with gemcitabine and doxorubicin, and hence sensitizes HCC cells towards doxorubicin and gemcitabine treatments [37]. This evidence concerns the gene ABCC13 and hepatocellular carcinoma.